SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ArQule, Inc. (ARQL)
An SI Board Since April 2003
Posts SubjectMarks Bans Symbol
545 40 0 ARQL
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
520Presented ysterday at USB Global Life Science Conference. Haven't listened tD.Lu-9/20/2011
519Stock up more than 10% on volume nearly double daily norm----wonder what is behiArthur Radley-9/20/2011
518A real sleeper! Maybe something to do with the 4 abstracts for presentations atD.Lu-4/2/2011
517Volume tripled today and price spiked nearly 10% and then up another 3% in A-H--Arthur Radley-4/1/2011
516I was looking at the cash position for ARQL and it appeared that they might be fArthur Radley-1/12/2011
515Needham & Company Reiterates a 'Buy' on ArQule (ARQL); Pivotal PhaseArthur Radley-1/5/2011
514seekingalpha.com Nice outline of ARQL at ESMO conference.Arthur Radley-10/25/2010
513Volume today.tom pope-8/31/2010
512seekingalpha.comArthur Radley-8/26/2010
511Good call, and then some.tom pope-8/26/2010
510Sutent plus erlotinib whiffs, leaving the door open for 197. >>NEW YORK, tuck-8/24/2010
509Earnings... With milestone payments, cash looks like enough to support about 10 pgo-neil-8/5/2010
508Daiichi Sankyo and Arqule for Ph 3 and SPA for ARQ 197 [plus erlotinib] in NSCLCpgo-neil-8/5/2010
507<i> inhibits c-Met in a non-ATP-competitive manner</i> It's my Biomaven-6/10/2010
506CELG also had benefit but that is about it. JonRobohogs-6/8/2010
505As mentioned......appears that only BMY is getting any benefit out of ASCO. ThiArthur Radley-6/7/2010
504My recollection may be faulty, but it seems to me that what we're seeing is tom pope-6/7/2010
503Tuck, Appears that someone finally looked at the data and came to the same conclArthur Radley-6/7/2010
502Good? Mixed bag. Superiority in non-squamous histology only (thank goodness ttuck-6/7/2010
501finance.yahoo.com Of all the biotechs that I follow, ARQL was the only one thatArthur Radley-6/5/2010
500>> Any idea why this is significant? << Well..... my data set is scaram(o)uche-6/5/2010
499stocks.investopedia.comArthur Radley-5/28/2010
498[ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid ttuck15/28/2010
497I got the annual report and proxy material this week......I don't remember tArthur Radley-4/23/2010
496Yeah, figured out that it was the phase II data and the need for material discloscaram(o)uche-4/23/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News